CTT Pharma CEO Outlines Strategic Initiatives for 2026 Commercialization of Micelle Thin-Film Technology

CTT Pharma CEO Ryan Khouri issued a letter to shareholders outlining the company's strategic direction and upcoming milestones. The company's patented micelle thin-film technology aims to provide better, faster, and more convenient oral drug delivery options, positioning CTT as a unique force in the industry. Khouri stated his immediate focus as CEO will be to bring micelle encapsulated vitamins, other bioactive supplement strips, and nicotine oral strips into manufacturing in 2026.

The company is in the final stages of preparing an S-1 filing that will enable access to funding from an equity line and transition CTT Pharma into an SEC reporting company. This move is expected to bring additional transparency and potentially attract a larger group of shareholders and investors. The company hopes to achieve SEC reporting status before the end of 2025, though it acknowledges this could extend into early 2026. Capital from the equity line will be directed toward manufacturing the patented technology, with Khouri emphasizing his commitment to managing share count and dilution carefully.

CTT is actively strengthening its team by adding regulatory experts to navigate approval processes for North American sales and plans to hire an individual with extensive experience in bringing commercial products to market. The company is also in the process of locating a manufacturing facility, with anticipation of identifying a building in the first quarter of 2026 and subsequently acquiring necessary production equipment. These manufacturing and commercialization plans operate independently from the timing of decisions regarding the company's partnership with Johns Hopkins University, which is part of an NIH grant utilizing CTT's technology as a smoking cessation alternative and still awaits funding decisions for clinical trials.

A significant development involves the acceptance of a scholarly review manuscript for publication on December 15, 2025. Submitted by CTT scientist Dr. Katharine Cole and company founder Dr. Pankaj Modi, the paper provides a comprehensive review of current research in micelle/oral dissolvable strip technology. This publication is expected to increase visibility and understanding of the scientific principles underlying CTT's platform, serving to educate shareholders, potential partners, and the broader scientific community. The company plans to distribute the publication to shareholders via news release after the publication date and schedule a conference call in the first quarter to discuss progress and upcoming initiatives.

Khouri also noted ongoing efforts to strengthen the company's patent portfolio, with plans to share additional information as developments occur. With capital now secured, the company is expanding its team, advancing toward manufacturing, and defining regulatory pathways to commercialization. The CEO expressed appreciation for shareholder support and indicated he looks forward to providing further updates on the company's progress in the near future.